Boston Scientific Corporation (BSX) Expands AI-Enhanced Heart Devices With FARAPULSE Approval

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Boston Scientific Corporation is one of them

Boston Scientific Corporation (NYSE:BSX) is emerging as a top AI-powered biotech stock by embedding artificial intelligence into its medical device portfolio, particularly in cardiology. Its AI strategy focuses on integrating advanced algorithms directly into revenue-generating devices like the WATCHMAN and FARAPULSE pulsed field ablation system, enhancing clinical outcomes and creating a “sticky” ecosystem for healthcare providers.

Recent developments highlight the FDA’s expanded approval of FARAPULSE for treating certain types of atrial fibrillation, a condition affecting nearly 60 million people globally. Boston Scientific Corporation (NYSE:BSX) also partners with AI platforms such as Anumana, which leverages data from millions of patients to improve diagnostics and treatment outcomes in electrophysiology and left atrial appendage closure (LAAC) procedures.

The firm combines internal R&D with strategic acquisitions and early-stage investments through its venture arm, enabling rapid commercialization of AI-enhanced technologies at scale. This approach supports expansion beyond cardiology into other areas such as endoscopy and urology, demonstrating the scalability of its AI initiatives across multiple medical divisions.

Boston Scientific Corporation (BSX) Expands AI-Enhanced Heart Devices With FARAPULSE Approval

Boston Scientific Corporation (NYSE:BSX) recently reported strong organic sales growth of 17% year-over-year, including 28% growth in its WATCHMAN device. Key upcoming milestones include the commercialization of the Cortex OptiMap system combined with FARAPULSE and further AI-driven product launches and partnerships that reinforce Boston Scientific’s leadership in AI-enabled medical technology.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.